Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...
The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomid...
The Global Health Innovative Technology (GHIT) Fund announced a total investment of approximately JPY 2 billion (USD 12.7 million1) in eight...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced it has amended its agreement with Takeda to develop and commercialize osavampator (NB...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai announced results from the Phase 3 LEAP-015 trial evaluating KEYTR...
Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for...
Advanced Genomics APAC Co., Ltd. (hereinafter referred to as "Advanced Genomics APAC," headquartered in Taiwan, Managing Director: Andy Chang) is pl...
Windward Bio, a private, clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases, a...
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Daikichiro Kobayashi, hereinafter “Meiji”) announce...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced the U.S. Food and Drug Administration (FDA) a...
Primo Biotechnology (“Primo”) announced a strategic partnership with SHINE Technologies, LLC, (“SHINE”) a global leader in nuclear ...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co-formulated wi...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) announced that Takeda received regulatory approval for HYQVIA® [Immune Globulin Infusion 10%...
VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP argenx's VYVGART® and VYVDURA portfoli...
© 2025 Biopharma Boardroom. All Rights Reserved.
